- Home
- ZVSA vs CYTO Comparison
ZVSA vs CYTO Comparison
Compare ZVSA & CYTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZVSA
- CYTO
- Stock Information
- Founded
- ZVSA 2014
- CYTO 2003
- Country
- ZVSA United States
- CYTO Bermuda
- Employees
- ZVSA N/A
- CYTO N/A
- Industry
- ZVSA Biotechnology: Pharmaceutical Preparations
- CYTO Biotechnology: Pharmaceutical Preparations
- Sector
- ZVSA Health Care
- CYTO Health Care
- Exchange
- ZVSA Nasdaq
- CYTO Nasdaq
- Market Cap
- ZVSA 2.3M
- CYTO 2.4M
- IPO Year
- ZVSA N/A
- CYTO N/A
- Fundamental
- Price
- ZVSA $2.46
- CYTO $0.77
- Analyst Decision
- ZVSA Strong Buy
- CYTO
- Analyst Count
- ZVSA 1
- CYTO 0
- Target Price
- ZVSA $240.00
- CYTO N/A
- AVG Volume (30 Days)
- ZVSA 116.5K
- CYTO 93.8K
- Earning Date
- ZVSA 11-12-2024
- CYTO 09-24-2024
- Dividend Yield
- ZVSA N/A
- CYTO N/A
- EPS Growth
- ZVSA N/A
- CYTO N/A
- EPS
- ZVSA N/A
- CYTO N/A
- Revenue
- ZVSA N/A
- CYTO N/A
- Revenue This Year
- ZVSA N/A
- CYTO N/A
- Revenue Next Year
- ZVSA N/A
- CYTO N/A
- P/E Ratio
- ZVSA N/A
- CYTO N/A
- Revenue Growth
- ZVSA N/A
- CYTO N/A
- 52 Week Low
- ZVSA $2.08
- CYTO $0.73
- 52 Week High
- ZVSA $62.30
- CYTO $17.20
- Technical
- Relative Strength Index (RSI)
- ZVSA 41.63
- CYTO 34.81
- Support Level
- ZVSA $2.08
- CYTO $0.74
- Resistance Level
- ZVSA $2.54
- CYTO $0.85
- Average True Range (ATR)
- ZVSA 0.27
- CYTO 0.06
- MACD
- ZVSA -0.01
- CYTO -0.01
- Stochastic Oscillator
- ZVSA 38.37
- CYTO 17.46
About ZVSA ZyVersa Therapeutics Inc.
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.
About CYTO Altamira Therapeutics Ltd.
Altamira Therapeutics Ltd is dedicated to developing therapeutics that address unmet medical needs. It is active in RNA therapeutics, allergy and viral infections, and inner ear disorders. Its product Bentrio is a drug-free nasal spray for personal protection against airborne viruses and allergens. The company's OligoPhore / SemaPhore platform is a versatile system that allows the complexation of therapeutic RNAs with a proprietary peptide to form a nanoparticle formulation. This formulation allows to deliver of therapeutic RNA by systemic administration to tissues affected by leaky vasculature, a hallmark of solid tumors and certain inflammatory conditions.